|
|
Zhaosheng Lin
Head of Biomarkers
Pfizer
 Nadine Cohen Head of Pharmacogenomics
Johnson & Johnson
 Mitchell B. Friedman Director of Toxicology
Takeda Global R&D
 Malcolm Mitchell Medical Director, Clinical Pharmacology
Eli Lilly
 Dr Russell Weiner Group Director
Bristol-Myers Squibb
|
Conference:
Pre-conference workshop
19 Oct 9am - 5pm
Day 1
20 Oct 8.30am - 5:30pm
Day 2
21 Oct 8.30am - 5:30pm
Post-conference workshop
22 Oct 9am - 5pm
Venue: Boston, MA, United States
› Email a friend
› Add this to my calendar
|
|
|
Martin Sanders,
Research Driector, Safety Pharmacology Hoffman-La Roche Inc Dr. Sanders is currently the Global Head of Safety Pharmacology in the Department of NonClinical Safety at Roche with over 23 years experience in pharmaceutical research and development. Over his career, Dr Sanders has employed both in vitro and in vivo pharmacology and safety models in working across discovery research projects that spanned therapeutic areas in GI, pulmonary, CNS, metabolic and cardiovascular diseases as well as contributing expertise to numerous early clinical development teams, serving on due diligence teams and providing an integrated data assessment for IND submissions as part of a compound’s preclinical safety evaluation. Appearing: Day One, Wednesday 20 October 2010 4.30pm Preclinical Cardiovascular Safety Which Would of Course Include QT Testing
- Overview of a typical Safety Pharmacology program for small molecules versus biologicals
- Preclinical cardiovascular evaluation- assessment: QT, hemodynamics and contractility
- Translation of preclinical data to the clinic- PK/PD modeling
Martin Sanders, Research Driector, Safety Pharmacology,
Hoffman-La Roche Inc |
|
|
|
|
|
Reserve an exhibition stand at the Exploratory Clinical Development World Americas exhibition - book early to ensure optimum stand placement!
| |
Reserve a stand
For details contact
Claire Conway on +44 (0) 207 608 7058 |
|
|
|
|
|
|
|
|
|
